We have recently demonstrated that the circulating level of LOX-1 ligand containing apoB (LAB) predicts the risk of cardiovascular events; however, as is the case in other assays measuring oxidized LDL (oxLDL), chemical unstability and inter-lot variance of standard oxLDL may limit the utility of measuring LAB. This study aimed to develop an alternative protein standard that is simultaneously recognized by LOX-1 and anti-apoB antibody instead of copper-oxidized LDL. Methods and Results: cDNAs encoding the variable regions of anti-LOX-1 monoclonal antibody were cloned from hybridomas and reorganized to express anti-LOX-1 single-chain variable fragment (Fv). cDNAs of four regions of human apoB (B1 to B4), which were reported to be epitopes of many anti-apoB antibodies, were also cloned. After confirming the respective reactivity of Fv and apoB fragments to LOX-1 and anti-apoB antibodies, cDNAs of Fv and apoB fragments were connected to express Fv-ApoB chimeric proteins. These fusion proteins were found to be recognized by both LOX-1 and anti-apoB antibodies. Among them, the fusion proteins of Fv-B1 and Fv-B3 gave saturable binding curves against immobilized LOX-1 when detected by anti-apoB antibodies. The binding curves of different Fv-B1 preparations to LOX-1 were almost identical while those of oxLDL varied among the preparations, suggesting better quality control of Fv-B1 preparations. Conclusions: The fusion proteins composed of Fv-form anti-LOX-1 antibody and apoB fragment are useful alternatives to copper-oxidized LDL in determining LAB, which would facilitate the application of modified LDL analyses to the clinical diagnosis and risk evaluation of cardiovascular disease.
Introduction
The high plasma concentration of low-density lipoprotein (LDL) is a hallmark risk factor for cardiovascular diseases. LDL undergoes modification in vivo, such as oxidation, glycation, and carbamylation, enzy-resistant to the development of atherosclerosis and cardiac injury after ischemia-reperfusion 13, 14) . Moreover, anti-LOX-1 antibody suppresses vascular lipid retention 15) . We have previously developed a sandwich enzymelinked immunosorbent assay (ELISA) to determine plasma/serum LAB using immobilized LOX-1 and anti-apoB antibody [16] [17] [18] [19] . The results showed that plasma LAB levels are substantially high in apoE-deficient mice and Watanabe Heritable Hyperlipidemic rabbits, representatives of atherosclerosis-prone animals. Compared to other assays measuring oxLDL with anti-oxLDL antibodies [20] [21] [22] , LAB ELISA more likely measures the biological activity of modified LDL represented by oxLDL rather than the absolute amount of oxidatively modified epitope(s), because the assay is a receptor-binding based measurement. Modified LDL is a heterogeneous lipoprotein with various modifications of lipid and protein moieties, which bind to the receptor with various binding affinities. Recently, we have shown in a community-based cohort study that a high LOX Index ([LAB] [soluble LOX-1]) value strongly predicts the risk of the incidence of cardiovascular diseases 17) . In particular, the hazard ratio for ischemic stroke was 3-fold higher in people with the highest quartile of LOX Index, implying the prognostic value of LOX Index for future diagnostic use.
The LAB assay as well as other anti-oxLDL antibody-based assays utilizes oxLDL prepared in vitro with copper ion as a standard. The oxidation degree of the copper-oxidized LDL, however, varies lot by lot, depending on the backgrounds of individuals from whom the plasma is derived, and the storage periods, even if the experimental conditions are constant. This limits the utilization of oxLDL and/or LAB as a clinical marker, although copper-oxidized LDL is a consistent ligand for LOX-1 23) . This study aimed to develop a protein standard for the LAB measurement, which is easier for quality control than oxLDL.
Aim
The present study was conducted to develop an alternative protein standard that is simultaneously recognized by LOX-1 and anti-apoB antibody instead of copper-oxidized LDL for determination of modified LDL activity.
Methods

Preparation of Fv
Mouse monoclonal anti-LOX-1 antibody (#10-1), which recognizes human LOX-1 expressed on the cell surface, was obtained by immunizing mice with the extracellular domain of human LOX-1 (61-273), as previously described 24) . Isotype was determined using a commercially available kit (mouse monoclonal antibody isotyping test kit; AbD, Oxford, UK). Total RNA was isolated from the hybridoma and cDNA was prepared. VH and VL cDNA sequences were determined by PCR using the Mouse Ig-primer set (Novagen, Gibbstown, NJ) and TAKARA Ex-taq DNA polymerase (Takara, Shiga, Japan). VH cDNA with IgG heavy chain secretion signal sequence cDNA was amplified by PCR using KOD DNA polymerase (TOYOBO, Osaka, Japan) and a primer pair of Fv-H-F and Fv-H-Linker R ( Table 1) . VL cDNA was amplified using a primer pair of Linker-Fv-L-F and Fv-L-R ( Table 1) . Each fragment was subsequently ligated at the linker sites by overlap-extension PCR using a primer pair of Fv-H-F and Fv-L-R . It was then subcloned into pcDNA6.2/V5/GW/D-TOPO vector (Invitrogen, CA, USA) using the pcDNA Gateway Directional TOPO Expression kit (Invitrogen). The product was digested at NotI and XbaI sites within the multi-cloning site and subcloned into pEF6/V5/His vector (Invitrogen) to be expressed with V5 and 6xHistidine tag (V5-His) at C-terminus. Fv was expressed by transfecting the construct using the FreeStyle 293 Expression System (Invitrogen) and purified using TALON Metal Affinity Resins (Takara). DNA sequences were determined after each subcloning using the ABI Prism Cycle sequencing kit (Applied Biosystems, CA, USA).
Cloning of Human apoB48 cDNA
Four pairs of primers were designed to generate human apoB48 cDNA (GenBank accession no. NM000384) fragments {F1: apoB-1-F/apoB-1864-R (apoB 1-1864); F2: apoB-1802-F/apoB-4005-R (apoB 1802-4005); F3: apoB-3973-F/apoB-5207-R (apoB 3973-5207); F4: apoB-5137-F/apoB-6540-R (apoB 5137-6540), Table 1} . Human liver cDNA was subjected to PCR amplification (Human MTC Panel ; Clontech, CA, USA). Each cDNA fragment was subcloned in pcDNA6.2/V5/GW/D-TOPO vector and the sequences were determined. The subcloned F1 and F2 were digested at NotI and EcoRV sites, located within the multi-cloning site and at apoB 1821 bp, respectively, and they were subsequently ligated to each other to generate apoB48 cDNA . Similarly, F3 and F4 were digested with NotI and SalI (5161 bp) and ligated to each other to obtain apoB48 cDNA (3973-6540). Finally, the apoB cDNA fragments (1-4005 bp and 3973-6540 bp) were digested at NotI and XhoI sites, located within the multi-cloning site and at apoB 3995 bp, respectively. They were mutually ligated to obtain human apoB48 cDNA and the sequence was confirmed.
Expression of apoB Fragment (B1-B4)
The obtained human apoB48 cDNA was subcloned in pcDNA6.2/V5/GW/D-TOPO vector and subjected to PCR amplification using four different pairs of primers ( Table 1) to generate four apoB48 cDNA fragments (B1-B4, Fig. 3 ). They were subcloned into pSecTaq/FRT/V5-His-TOPO vector (Invitrogen) with Ig secretion signal and V5-His tag to be fused at N-and C-termini, respectively, and the sequences were confirmed. The proteins were expressed using the FreeStyle 293 expression system and purified with TALON Metal Affinity Resins.
Generation of Fv-apoB Fusion Proteins (Fv-B1~B4)
Fusion proteins were generated by connecting one of the apoB fragments (B1-B4) to the C-terminus of Fv with linker sequences (Fig. 1) . pcDNA6.2/V5/ GW/D-TOPO constructs of Fv and each apoB fragment cDNA were subjected to PCR with a primer pair of Fv-H-F and Fv-L-Linker-R, and apoB primer sets (B1: Linker-B1-F/B1-R, B2: Linker-B2-F/B2-R, B3: Linker-B3-F/B3-R, or B4: Linker-B4-F/B4-R) ( Table 1) . Obtained Fv cDNA and the respective apoB cDNA were connected with overlap-extension PCR using a primer pair of Fv-H-F and the respective reverse primers (B1-R, B2-R, B3-R or B4-R). Each product was subcloned into pcDNA6.2/V5/GW/ D-TOPO vector and the sequences were confirmed. They were digested with NotI and XbaI and cloned into pEF6/V5/His vector, with V5 and His tag fused Table 1 . PCR primers used in this study Primer Sequence
at the C-terminus. The proteins were expressed using the Free Style 293 expression system and purified with TALON Metal Affinity Resins.
ELISA
The bindings of anti-LOX-1 antibodies (#10-1, Fv and fusion proteins) to LOX-1 or those of antiapoB antibodies to apoB and fusion proteins were determined with ELISA. A 384-well plate (Greiner, Frickenhausen, Germany) was coated and incubated overnight at 4 with one of the following proteins (0.25 g/well): recombinant human LOX-1 (61-273) 16) , B1, B2, Fv-B1~B4, BSA (Sigma, St Louis, MO), or apoB (Sigma). The wells were washed with PBS and blocked with 20% Immunoblock (DS Pharma, Osaka, Japan) for 1 h at room temperature. Following PBS washing, mouse monoclonal anti-LOX-1 antibody (#10-1), Fv, Fv-B1~B4, chicken monoclonal antiapoB antibody 16) 
Western Blotting
To analyze the binding to anti-apoB antibodies, apoB fragments (B1-B4), Fv, and fusion proteins (Fv-B1~B4) were subjected to SDS-PAGE under nonreducing conditions, and transferred to a PVDF membrane. After blocking with PBS containing 0.1% Tween 20 (PBS-T) and 5% skim milk (Morinaga, Tokyo, Japan), the membrane was incubated for 1 h with (i) chicken monoclonal anti-apoB antibody (1 g/mL in PBS-T containing 5% skim milk) followed by treatment with HRP-labeled donkey anti-chicken IgY (1:4000 in PBS-T containing 5% skim milk), (ii) HRP-labeled sheep anti-human apoB polyclonal antibody (1:5000 in PBS-T containing 5% skim milk), or To analyze the binding to each fusion protein, recombinant human LOX-1 (61-273) and BSA (negative control) were subjected to SDS-PAGE under nonreducing conditions and transferred to a PVDF membrane. After blocking with 100% BlockAce (DS Pharma), the membrane was incubated with Fv or fusion proteins (5 g/mL in Can Get Signal Immunoreaction Enhancer Solution 1; TOYOBO). The membrane was subsequently treated with HRP-labeled mouse anti-V5 tag ( 2000 in Can Get Signal Immunoreaction Enhancer Solution 2; TOYOBO).
The binding of the proteins was detected with Immobilon Western Chemiluminescent HRP Substrate (Millipore) using LAS-4000 mini (GE Healthcare).
Preparation of Lipoproteins
LDL (density: 1.019-1.063 g/mL) was isolated by sequential ultracentrifugation from freshly obtained human plasma. LDL was oxidatively modified by exposing to 7.5 M CuSO4 in PBS for 16 h at 37 as described previously 19) .
Sandwich ELISA for LAB
The binding of the fusion protein and oxLDL to LOX-1 was conducted as previously reported 17) . In brief, a LOX-1-coated plate was blocked with 3% BSA in 10 mM HEPES-buffered saline (pH 7.4). After washing with PBS, the plate was incubated with fusion protein or oxLDL in HEPES/EDTA/BSA buffer (10 mM HEPES, 150 mM NaCl, 2 mM EDTA and 5% BSA, pH 7.4) for 2 h. After three washes with PBS, the plate was further incubated with chicken monoclonal anti-apoB antibody followed by HRPlabeled donkey anti-chicken IgY or HRP-labeled sheep anti-human apoB polyclonal antibody for 1 h. After five washes with PBS, HRP activity was measured with TMB solution (Bio-Rad).
Results and Discussion
Strategy of the Construction of Fv-apoB Fragment Fusion Protein
This study was aimed to develop an alternative protein standard replacing copper-oxidized LDL, which simultaneously binds to both LOX-1 and anti-apoB antibody in modified LDL sandwich ELISA. As illustrated in Fig. 1 , we took the strategy of preparing artificial fusion proteins to meet this criterion. Anti-LOX-1 single-chain variable fragment (Fv) was prepared and fused with apoB fragments with immunogenicity against anti-apoB antibody. Fv is a fusion protein connecting VH and VL regions in immunoglobulin that rec- Fv Bound to LOX-1 cDNA encoding variable regions (VH, VL) of mouse anti-LOX-1 monoclonal antibody (#10-1) 24) was cloned from the hybridoma and cDNA sequences were determined. Complementarity determining regions (CDR) were confirmed from deduced amino acid sequences as previously reported ( Fig. 2A ) 25) . Then, cDNAs for VH and VL were connected to express Fv, and Fv protein was synthesized and purified. Subsequently, the binding of Fv to immobilized recombinant human LOX-1, a capture protein utilized in sandwich ELISA, was examined 16, 17) . The results showed that Fv specifically bound to immobilized LOX-1 in a dose-dependent manner with almost identical affinity to #10-1 (Fig. 2B) .
Anti-apoB Antibody Recognized the apoB Fragments B1 and B2
cDNAs encoding parts of human apoB48 (B1, amino acids 28-217; B2, amino acids 427-596; B3, amino acids 977-1063; B4, amino acids 1462-1552, Fig. 3A) were cloned as potential anti-apoB antibody binding proteins since the amino acid regions of B1 to B4 reportedly include the epitope regions for 15 mouse monoclonal anti-apoB antibodies 26, 27) . Each recombinant protein was prepared as a protein tagged with V5 at C-terminus expressed in HEK293 cells, as described in Materials and Methods. Western blotting analysis using the antibody for V5-tag showed that B1 and B2 were released in the culture media (B1, 35 kDa; B2, 23 kDa) (Fig. 3B) . Chicken monoclonal anti-apoB and sheep polyclonal anti-apoB antibody recognized B1 and B2 in the culture media, respectively (Fig. 3B) . We further examined whether B1 and B2 purified from the culture media were recognized by the anti-apoB antibodies in ELISA. In accordance with the results obtained by Western blotting, chicken monoclonal anti-apoB antibody recognized immobilized B1 as well as full-length apoB in a concentrationdependent manner while it failed to bind to B2 (Fig. 3C) . In contrast, sheep polyclonal anti-apoB antibody recognized B2 and full-length apoB in a concentration-dependent manner. B1 was slightly recognized only at high concentrations of the polyclonal antibody.
Fv-apoB Fragment Fusion Proteins Bound to Both LOX-1 and Anti-apoB Antibodies
In the next series of experiments, fusion proteins of Fv and each apoB fragment were generated and characterized (Fig. 4A) . The culture media of HEK293 expressing Fv and Fv-B1~B4 were subjected to purification with His affinity resin and Western blotting. The results showed that all the proteins were released in the culture medium, as detected with the antibody for V5-tag (Fig. 4A) . All the fusion proteins retained the activity of binding to LOX-1 on the PVDF membrane after SDS-PAGE separation, as evidenced by a (Fig. 4B) . Moreover, an antibody for the protein tag V5 showed that all the purified fusion proteins bound to immobilized LOX-1 on the ELISA plate in a concentration-dependent manner, with Fv-B1 and Fv-B3 displaying comparable affinity to Fv (Fig. 4C) . No fusion proteins bound to immobilized BSA at significant levels (OD 0.05) (data not shown).
The fusion proteins also retained antigenecity to anti-apoB antibodies. Fv-B1 on the PVDF membrane separated by SDS-PAGE was exclusively detected with chicken monoclonal anti-apoB antibody (Fig. 5A) . On the other hand, sheep polyclonal anti-apoB antibody significantly recognized Fv-B2 and Fv-B3, and faintly recognized Fv-B1 and Fv-B4 (Fig. 5A) . In accordance with these results, chicken monoclonal antibody exclusively bound to immobilized Fv-B1 in a concentration-dependent manner while sheep polyclonal antibody bound to Fv-B1, Fv-B2, and Fv-B3 ( Fig. 5B and C) .
Fv-B1 showed Minimum Inter-Lot Variances Suitable for a Standard Protein
Thus, we obtained several fusion proteins bound to both immobilized LOX-1 and anti-apoB antibodies in a concentration-dependent manner. Here we addressed whether the fusion proteins were applicable as alternative standards to copper-oxidized LDL in sandwich ELISA for LAB. As shown in Fig. 6 , chicken monoclonal anti-apoB antibody exclusively detected the binding of Fv-B1 to immobilized LOX-1. On the other hand, sheep polyclonal anti-apoB antibody recognized the binding of Fv-B1, Fv-B2, and Fv-B3 to immobilized LOX-1. Finally, three sets of Fv-B1 were prepared and the binding curves were compared in sandwich ELISA for LAB. As shown in Fig. 7A , they A B displayed almost identical binding curves, indicating minimal quality variation among the standard protein preparations (Fig. 7A) . Copper-oxidized LDL of different preparations displayed larger differences in the binding curves compared with Fv-B1 (Fig. 7B) .
Although the binding affinity of Fv-B1 is less than oxLDL, we could reproducibly measure LAB activity utilizing Fv-B1 as the standard protein equivalent. In this case, the absolute amount of the standard is of no importance. Therefore, LAB activity measured by the new standard would be expressed as "Fv-B1 equivalent ( g/mL)" or "unit" for clinical use.
Perspectives
To date, cross-sectional studies using oxLDLspecific antibodies have demonstrated that circulating oxLDL levels are high in patients with cardiovascular diseases 21, [28] [29] [30] . Furthermore, our recent cohort study using sandwich ELISA for LAB highlighted the importance of circulating modified LDL in the development of cardiovascular diseases 17) . Of particular importance, while anti-oxLDL monoclonal antibodies recognize specific epitopes of oxLDL, such as oxidized phospholipids and modified apoB 20, 21, 31) , LOX-1 recognizes oxLDL of various degrees of oxidation 23) . Moreover, LAB, a LOX-1 ligand containing apoB, includes other atherogenic lipoproteins, such as carbamylated LDL, remnant-like lipoprotein particle and electronegative LDL since these lipoproteins are known to be LOX-1 ligands 8, 9, 32, 33) . Therefore, the circulating levels of LAB encompass a considerable range of atherogenic lipoproteins, and their biological activities are more likely to predict the risk of cardiovascular diseases than measuring one particular epitope of oxLDL.
In summary, we successfully developed four fusion proteins that simultaneously bind to LOX-1 and anti-apoB antibodies. In particular, Fv-B1 is highly applicable as a standard protein for the LAB assay since it is recognized by chicken monoclonal anti-apoB antibody and displays minimum inter-lot variances. The use of fusion protein would accelerate the measurement of LAB and LOX Index on a larger scale to be established for future clinical use.
Conclusions
Fv-B1 binds to LOX-1 and is simultaneously recognized by monoclonal anti-apoB antibody. It would facilitate the application of modified LDL analyses to the clinical diagnosis and risk evaluation of cardiovascular disease.
